735 related articles for article (PubMed ID: 17074845)
1. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
[TBL] [Abstract][Full Text] [Related]
2. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
[TBL] [Abstract][Full Text] [Related]
3. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B
Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772
[TBL] [Abstract][Full Text] [Related]
4. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus.
Eliasson DG; Helgeby A; Schön K; Nygren C; El-Bakkouri K; Fiers W; Saelens X; Lövgren KB; Nyström I; Lycke NY
Vaccine; 2011 May; 29(23):3951-61. PubMed ID: 21481325
[TBL] [Abstract][Full Text] [Related]
5. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
7. Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.
Xu Y; Zhu B; Wang Q; Chen J; Qie Y; Wang J; Wang H; Wang B; Wang H
FEMS Immunol Med Microbiol; 2007 Dec; 51(3):480-7. PubMed ID: 17919299
[TBL] [Abstract][Full Text] [Related]
8. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
Akhiani AA; Stensson A; Schön K; Lycke N
Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
[TBL] [Abstract][Full Text] [Related]
9. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.
Dietrich J; Andersen C; Rappuoli R; Doherty TM; Jensen CG; Andersen P
J Immunol; 2006 Nov; 177(9):6353-60. PubMed ID: 17056566
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
Tang C; Yamada H; Shibata K; Maeda N; Yoshida S; Wajjwalku W; Ohara N; Yamada T; Kinoshita T; Yoshikai Y
J Infect Dis; 2008 May; 197(9):1263-74. PubMed ID: 18422438
[TBL] [Abstract][Full Text] [Related]
11. An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis.
Wang QL; Pan Q; Ma Y; Wang K; Sun P; Liu S; Zhang XL
Vaccine; 2009 Nov; 27(48):6712-22. PubMed ID: 19733584
[TBL] [Abstract][Full Text] [Related]
12. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.
Bennekov T; Dietrich J; Rosenkrands I; Stryhn A; Doherty TM; Andersen P
Eur J Immunol; 2006 Dec; 36(12):3346-55. PubMed ID: 17109467
[TBL] [Abstract][Full Text] [Related]
13. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
Majlessi L; Simsova M; Jarvis Z; Brodin P; Rojas MJ; Bauche C; Nouzé C; Ladant D; Cole ST; Sebo P; Leclerc C
Infect Immun; 2006 Apr; 74(4):2128-37. PubMed ID: 16552042
[TBL] [Abstract][Full Text] [Related]
14. Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice.
Xu J; Xu W; Chen X; Zhao D; Wang Y
Vaccine; 2008 Aug; 26(35):4519-25. PubMed ID: 18598729
[TBL] [Abstract][Full Text] [Related]
15. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
[TBL] [Abstract][Full Text] [Related]
16. A novel DNA vaccine for protective immunity against virulent Mycobacterium bovis in mice.
Liu S; Gong Q; Wang C; Liu H; Wang Y; Guo S; Wang W; Liu J; Shao M; Chi L; Zhao K; Wang Z; Shi Y; Huang Y; Guli A; Zhang C; Kong X
Immunol Lett; 2008 May; 117(2):136-45. PubMed ID: 18339431
[TBL] [Abstract][Full Text] [Related]
17. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
Lycke N
Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
[TBL] [Abstract][Full Text] [Related]
18. Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule.
Luo Y; Jiang W; Da Z; Wang B; Hu L; Zhang Y; An R; Yu H; Sun H; Tang K; Tang Z; Wang Y; Jing T; Zhu B
Scand J Immunol; 2012 Mar; 75(3):293-300. PubMed ID: 22117839
[TBL] [Abstract][Full Text] [Related]
19. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
[TBL] [Abstract][Full Text] [Related]
20. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]